Literature DB >> 25997995

miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.

Wenjun Yin1, Yuehua Nie2, Zhiwei Zhang1, Liming Xie3, Xiusheng He1.   

Abstract

Mounting evidence suggests that microRNAs (miRNAs) play important roles in the development of cancer by targeting expression of tumor-related genes. In the present study, downregulation of miR-193b was observed in hepatocellular carcinoma (HCC) tissues and HCC cell lines by quantitative RT-PCR analyses, suggesting that miR-193b is a tumor-suppressor in HCC. More importantly, miR-193b significantly enhanced the cytotoxicity of cisplatin in HepG2 cells by targeting Mcl-1. Knockdown of the Mcl-1 gene by specific siRNA exhibited a function similar to miR-193b on sensitizing HepG2 cells to cisplatin-inducing cytotoxicity. Furthermore, the miR-193b-induced sensitization of HepG2 cells to cisplatin cytotoxicity was abolished by the transfection of Mcl-1 expression plasmid that lacked the 3'-untranslated region (3'-UTR). In addition, activation of caspase-3 was needed for sensitization by miR-193b to cisplatin-mediated cell death. Thus, the present study revealed the downregulation of miR-193b in HCC cells and illustrated a synergistic effect on cisplatin-induced apoptosis by targeting Mcl-1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25997995     DOI: 10.3892/or.2015.3996

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.

Authors:  Haifei He; Wei Tian; Hailong Chen; Kai Jiang
Journal:  Tumour Biol       Date:  2015-08-23

2.  Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-α-treated triple-negative breast cancer cells.

Authors:  Like Wo; Dezhao Lu; Xidong Gu
Journal:  Tumour Biol       Date:  2016-07-30

3.  miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.

Authors:  Sumei Zhou; Qidi Huang; Shurong Zheng; Kuailu Lin; Jie You; Xiaohua Zhang
Journal:  Tumour Biol       Date:  2015-12-10

4.  Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer.

Authors:  Zhiqiang Ye; Rutian Hao; Yefeng Cai; Xiaobo Wang; Guanli Huang
Journal:  Tumour Biol       Date:  2015-10-26

Review 5.  MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas.

Authors:  Sumadi Lukman Anwar; Ulrich Lehmann
Journal:  J Clin Med       Date:  2015-08-18       Impact factor: 4.241

6.  miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3.

Authors:  Dennis Sohn; Dominik Peters; Roland P Piekorz; Wilfried Budach; Reiner U Jänicke
Journal:  Oncotarget       Date:  2016-03-29

7.  miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1.

Authors:  Guinv Hu; Xiaokang Zhao; Jiang Wang; Liting Lv; Chaoqun Wang; Liang Feng; Liangqiong Shen; Weili Ren
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

8.  Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.

Authors:  Srinivasulu Yerukala Sathipati; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

9.  MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.

Authors:  Changlong Xu; Liang Shi; Weilai Chen; Peipei Fang; Jie Li; Lingxiang Jin; Zhenzhen Pan; Chenwei Pan
Journal:  Oncotarget       Date:  2017-06-27

10.  MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma.

Authors:  Yangbai Sun; Nengbin He; Yang Dong; Chaoyin Jiang
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.